Zura Bio Limited filed a Form 8-K with the U.S. Securities and Exchange Commission on August 11, 2026, disclosing its second quarter 2026 financial results via press release and an updated corporate presentation.
Key Highlights
- Date of report: August 11, 2026, also the date of earliest event reported.
- Q2 2026 results: The company issued a press release on August 11, 2026, announcing its second quarter 2026 financial results, furnished as Exhibit 99.1.
- Corporate presentation: An updated corporate presentation dated August 11, 2026, was provided for use at conferences and investor meetings, filed as Exhibit 99.2.
- Emerging growth company: Zura Bio Limited is designated an emerging growth company under applicable SEC rules.
- Signed by: Kim Davis, Chief Operating Officer, Chief Legal Officer and Corporate Secretary.
Zura Bio Announces Q2 2026 Results and Updated Investor Presentation
Zura Bio Limited (NASDAQ:ZURA), a Cayman Islands-incorporated company with principal executive offices in Henderson, Nevada, filed a current report on August 11, 2026, covering two disclosure items. Under Item 2.02, the company disclosed that it issued a press release on August 11, 2026, announcing its second quarter 2026 financial results. That press release was furnished as Exhibit 99.1 and incorporated by reference into the filing.
Under Item 7.01, the company disclosed that it provided an updated corporate presentation on August 11, 2026, described as material "that may be used in connection with upcoming presentations at conferences and investor meetings." The presentation was filed as Exhibit 99.2 and, according to the filing, may also be accessed through the "News & Events" section of the company's investor relations website at investors.zurabio.com.
The filing notes that information furnished under Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, and shall not be subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. The report was signed by Kim Davis in her capacity as Chief Operating Officer, Chief Legal Officer and Corporate Secretary.
What Was Disclosed
Zura Bio Limited reported the release of its second quarter 2026 financial results and an updated corporate presentation, both dated August 11, 2026, furnished as exhibits to this current report filing.



Please wait processing your request...